Aurora Cannabis (ACB) Stock Forecast and Price Target (2026)

Sell-side coverage follows trading volume and banking relationships, so smaller companies, recent listings, and names outside the major indices often carry little or none. That is the situation with ACB. It says nothing about the quality of the business, but it does mean there is no informed average to anchor to, and that any single target you find elsewhere is one analyst's model rather than a consensus.

Aurora trades below book value and under one times sales, a discount that tracks its losses and dilution history, but in October 2026 the price is also being set by the Curaleaf bid: the shares sit about 20% below the roughly $5 headline offer, since most of that value is in Curaleaf stock and the board opposes it. Be cautious with per-share comparisons across time given the reverse-split history, and check the current share count, cash position, and the status of the offer directly in filings. Fiscal second-quarter results are expected in early November 2026.

For the fiscal year ending Mar 2027, the 6 analysts publishing estimates on ACB expect earnings of -0.17 CAD per share and revenue of 295 million CAD (-8.0%).

Estimates are the most widely published forecast there is: many more analysts model a company's earnings than publish a price target on it. They are also revised constantly, and the direction of those revisions into a report is often more informative than the level. Aurora Cannabis next reports around November 4, 2026 (an estimated date), which is when these figures get tested against actual results.

Not a published one. Analyst price targets run to about twelve months, occasionally two years, and the firms covering ACB do not put out a 2030 number. Anything presenting one is extrapolating a growth rate rather than reporting research, and a figure produced that way tells you about the assumption chosen, not about the company.

What can be said over a long horizon is what the current price already assumes about the business, which is a question the filings answer and a forecast cannot.

That is the more useful frame for a ten-year question. A share price is the market’s estimate of future cash flows discounted to today, so the multiple is already a statement about growth. The long-horizon question is whether Aurora Cannabis can deliver what is priced in, and what would have to change for that to break. Both are answerable from the drivers and risks below. A number for 2030 is not.

In short: the drivers cited most often are International medical cannabis growth, The Curaleaf bid and strategic review, Path to sustained profitability. The risk cited most often against it is the central risk is Aurora's capital-structure history: repeated equity raises and a cumulative reverse-split history (roughly 1-for-120 over time) have destroyed per-share value, and further dilution would do so again.

Both sides are worked through properly, with the high and low targets used as the bull and bear anchors, on the ACB is it a buy page. This page deliberately stops at the numbers.